(0.34%) 5 117.45 points
(0.31%) 38 358 points
(0.33%) 15 980 points
(-0.85%) $83.14
(2.96%) $1.980
(-0.03%) $2 346.60
(-0.10%) $27.51
(3.10%) $950.65
(-0.05%) $0.934
(0.00%) $11.02
(-0.30%) $0.798
(1.84%) $93.57
Quarter results today
(bmo 2024-04-29)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes...
Stats | |
---|---|
本日の出来高 | 2 452.00 |
平均出来高 | 6 508.00 |
時価総額 | 654.41B |
EPS | €0 ( 2024-02-06 ) |
Last Dividend | €1.130 ( 2023-08-14 ) |
Next Dividend | €0 ( N/A ) |
P/E | 128.18 |
ATR14 | €0.608 (0.09%) |
ボリューム 相関
Eli Lilly and Co 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Eli Lilly and Co 相関 - 通貨/商品
Eli Lilly and Co 財務諸表
Annual | 2023 |
収益: | €34.12B |
総利益: | €27.04B (79.25 %) |
EPS: | €5.82 |
FY | 2023 |
収益: | €34.12B |
総利益: | €27.04B (79.25 %) |
EPS: | €5.82 |
FY | 2022 |
収益: | €28.54B |
総利益: | €21.91B (76.77 %) |
EPS: | €6.93 |
FY | 2021 |
収益: | €28.32B |
総利益: | €21.01B (74.18 %) |
EPS: | €5.83 |
Financial Reports:
No articles found.
Eli Lilly and Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.980 (N/A) |
€0.980 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.490 | 2009-05-13 |
Last Dividend | €1.130 | 2023-08-14 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 41 | -- |
Total Paid Out | €27.35 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.68 | -- |
Div. Sustainability Score | 5.72 | |
Div.Growth Potential Score | 6.05 | |
Div. Directional Score | 5.89 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PBB.DE | Ex Dividend Junior | 2023-05-26 | Annually | 0 | 0.00% | |
APC.F | Ex Dividend Knight | 2023-08-11 | Quarterly | 0 | 0.00% | |
HHFA.DE | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
SAP.DE | Ex Dividend Knight | 2023-05-12 | Annually | 0 | 0.00% | |
CBHD.DE | Ex Dividend Knight | 2023-05-15 | Semi-Annually | 0 | 0.00% | |
KHNZ.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
TNE5.DE | Ex Dividend Junior | 2023-12-12 | Semi-Annually | 0 | 0.00% | |
DR0.DE | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
MUB.DE | Ex Dividend Junior | 2023-08-11 | Annually | 0 | 0.00% | |
7BP.F | Ex Dividend Knight | 2023-09-06 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.154 | 1.500 | 6.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0819 | 1.200 | 7.27 | 8.73 | [0 - 0.3] |
returnOnEquityTTM | 0.474 | 1.500 | 5.85 | 8.77 | [0.1 - 1] |
payoutRatioTTM | 0.777 | -1.000 | 2.23 | -2.23 | [0 - 1] |
currentRatioTTM | 0.943 | 0.800 | -0.287 | -0.230 | [1 - 3] |
quickRatioTTM | 0.523 | 0.800 | -1.632 | -1.305 | [0.8 - 2.5] |
cashRatioTTM | 0.103 | 1.500 | -0.537 | -0.806 | [0.2 - 2] |
debtRatioTTM | 0.394 | -1.500 | 3.43 | -5.15 | [0 - 0.6] |
interestCoverageTTM | 15.00 | 1.000 | 5.56 | 5.56 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.47 | 2.00 | 8.51 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -3.32 | 2.00 | -1.660 | -3.32 | [0 - 20] |
debtEquityRatioTTM | 2.34 | -1.500 | 0.633 | -0.949 | [0 - 2.5] |
grossProfitMarginTTM | 0.792 | 1.000 | 0.126 | 0.126 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.214 | 1.000 | 7.73 | 7.73 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.168 | 1.000 | -0.177 | -0.177 | [0.2 - 2] |
assetTurnoverTTM | 0.533 | 0.800 | 9.78 | 7.82 | [0.5 - 2] |
Total Score | 5.72 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 133.88 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.474 | 2.50 | 7.33 | 8.77 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -3.32 | 2.00 | -1.107 | -3.32 | [0 - 30] |
dividendYielPercentageTTM | 0.635 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.47 | 2.00 | 8.51 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.777 | 1.500 | 2.23 | -2.23 | [0 - 1] |
pegRatioTTM | 7.68 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.124 | 1.000 | 9.39 | 0 | [0.1 - 0.5] |
Total Score | 6.05 |
Eli Lilly and Co
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。